Galectin Therapeutics (GALT) Other Accumulated Expenses (2011 - 2015)

Galectin Therapeutics' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $6000.0 for Q3 2015.

• On a quarterly basis, Other Accumulated Expenses rose 200.0% year-over-year to $6000.0 in Q3 2015; TTM through Sep 2015 was $6000.0, a 200.0% increase from a year earlier, with the FY2014 full-year figure at $7000.0, down 68.18% from the prior year.
• Other Accumulated Expenses retreated to $6000.0 in Q3 2015 per GALT's latest filing, from $7000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $98000.0 in Q1 2014 and bottomed at $2000.0 in Q2 2014.
• The 5-year median for Other Accumulated Expenses is $10000.0 (2012), against an average of $29800.0.
• Biggest YoY gain for Other Accumulated Expenses was 790.91% in 2014; the steepest drop was 96.3% in 2014.
• Year by year, Other Accumulated Expenses stood at $97000.0 in 2011, then plunged by 89.69% to $10000.0 in 2012, then surged by 120.0% to $22000.0 in 2013, then sank by 68.18% to $7000.0 in 2014, then slipped by 14.29% to $6000.0 in 2015.
• Per Business Quant, the three latest GALT Other Accumulated Expenses figures stand at $6000.0 (Q3 2015), $7000.0 (Q2 2015), and $72000.0 (Q1 2015).